Founded

Address

Flagship Ventures
One Memorial Drive
7th Floor
Cambridge, MA 02142
United States

Open map


Recent investment activity

KANDO id: 30843

Corporate information

Founders
Registration country

Company type

Venture capital firm

Relation

Renamed to

Funding rounds

Investment preferences

Top investment portfolio themes
software (1)  
healthcare (1)  

Actual initial investment stage
N/A (3)

Investment activity status
Not investing

Selected investments

Displaying 76 - 89 of 89
Profile Country Date Sort descending Funding
Kovio Inc Developer of a new category of semiconductor products using printed silicon electronics and thin film technology Series E
Receptos Inc [] Series A
Acceleron Pharma Inc Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. Series D Follow-on investment
Oasys Water Inc N/A
Advanced Electron Beams Inc (AEB) Provider of electron beam energy technology products and solutions worldwide. N/A
Tetraphase Pharmaceuticals Inc A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. Series C
ExactCost Inc A financial performance solutions company for the healthcare industry dedicated to improving healthcare performance and clinical quality. N/A
TransMedics Inc N/A
Kovio Inc Developer of a new category of semiconductor products using printed silicon electronics and thin film technology Venture
Avedro Inc A medical device company focused on vision correctional devices and has developed innovative ophthalmology solutions for the Lasik and myopia markets. Series C
Acceleron Pharma Inc Biopharmaceutical company developing protein therapeutics for cancer and orphan diseases. Series F Follow-on investment
Tangent Medical Technologies Inc N/A
Breathable Foods Inc A company pioneering novel devices and formulations for the delivery of nutrients and pharmaceuticals through breathing. N/A
Blend Therapeutics Inc A biotechnology company pioneering controlled combination medicines that overcome the limitations of conventional combination therapy. Series A

Current team

Past employees

Selected Products / Customers

Financials